AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27587282 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg)
Number of subjects: 0
Study 27587282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24955503 — intervention group
Group type: COMPARATOR
Intervention: General physical activity (GPA)
Number of subjects: 83
Study 24955503 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA and additional strength training of the neck and shoulder (SST)
Number of subjects: 83
Study 24955503 — intervention group
Group type: EXPERIMENTAL
Intervention: SST
Number of subjects: 83
Study 24955503 — intervention group
Group type: COMPARATOR
Intervention: GPA
Number of subjects: 83
Study 22742765 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem (2 g loading dose followed by 4 g continuous infusion over 24 hours)
Number of subjects: 240
Study 22742765 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of meropenem (2 g over 30 minutes every 8 hours)
Number of subjects: 240
Study 22742765 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem
Number of subjects: 240
Study 22742765 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of meropenem
Number of subjects: 240
Study 20152514 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based prostate cancer screening
Number of subjects: 0
Study 17620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial pramipexole treatment
Number of subjects: 0
Study 17620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 0
Study 17620552 — intervention group
Group type: EXPERIMENTAL
Intervention: >5 systems with a comorbid illness
Number of subjects: 0
Study 17620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 0
Study 17620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid cardiac disease
Number of subjects: 0
Study 17620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >= 65
Number of subjects: 0
Study 17620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination score >28
Number of subjects: 0
Study 15319305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslexic adults
Number of subjects: 16
Study 15319305 — intervention group
Group type: COMPARATOR
Intervention: Normal-reading adults
Number of subjects: 16
Study 11903069 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 20
Study 11903069 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 20
Study 11903069 — intervention group
Group type: COMPARATOR
Intervention: Postoperative period
Number of subjects: 20
Study 11903069 — intervention group
Group type: COMPARATOR
Intervention: Postoperative 6-hydroxymelatonin sulphate excretion
Number of subjects: 20
Study 9707656 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Care Travelling Record (PCTR)
Number of subjects: 21
Study 9707656 — intervention group
Group type: COMPARATOR
Intervention: Control (no PCTR)
Number of subjects: 21
Study 8521893 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (orchiectomy plus cyproterone acetate)
Number of subjects: 294
Study 8521893 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (orchiectomy plus placebo)
Number of subjects: 294
Study 2404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 18
Study 2404429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 392621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 15
Study 392621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31009939 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1066
Study 31009939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILS)
Number of subjects: 1066
Study 31009939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1066
Study 28295934 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg once daily
Number of subjects: 57
Study 28295934 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 300 U/mL (IGlar-U300) 0.4 U/kg once daily
Number of subjects: 57
Study 26345920 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) therapy under nasal endoscopy guidance
Number of subjects: 120
Study 26345920 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid nasal spray and oral cetirizine hydrochloride (Control)
Number of subjects: 120
Study 23712736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraturbinal MAIT (group 1)
Number of subjects: 60
Study 23712736 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraturbinal MAIT (group 2)
Number of subjects: 60
Study 23712736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intraturbinal and Extraturbinal MAIT)
Number of subjects: 60
Study 21311216 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEEDA under 2-1-1 regimen (group A)
Number of subjects: 112
Study 21311216 — intervention group
Group type: COMPARATOR
Intervention: Rabipur under 2-1-1 regimen (group B)
Number of subjects: 112
Study 21311216 — intervention group
Group type: COMPARATOR
Intervention: SPEEDA under Essen 5-dose regimen (group C)
Number of subjects: 112
Study 21311216 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 112
Study 17459542 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a Baby programme
Number of subjects: 170
Study 17459542 — intervention group
Group type: COMPARATOR
Intervention: Regular programme
Number of subjects: 170
Study 17459542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programmes
Number of subjects: 170
Study 17311051 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (70 mg/day for 24 weeks)
Number of subjects: 18
Study 17311051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15016285 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo condition (memory cues from school class group photos)
Number of subjects: 45
Study 15016285 — intervention group
Group type: COMPARATOR
Intervention: No-photo condition
Number of subjects: 45
Study 11282905 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 120
Study 11282905 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 120
Study 11282905 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study 15321207 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position with 15-20 degrees right flank elevation
Number of subjects: 60
Study 15321207 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position for 10 min after injection
Number of subjects: 60
Study 15321207 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position for 5 min then right lateral position for 5 min
Number of subjects: 60
Study 15321207 — intervention group
Group type: COMPARATOR
Intervention: All groups (S, L, L+R)
Number of subjects: 60
Study 7840400 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg esmolol
Number of subjects: 63
Study 7840400 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg esmolol
Number of subjects: 63
Study 7840400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 3048753 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted 0.5% bupivacaine
Number of subjects: 100
Study 3048753 — intervention group
Group type: COMPARATOR
Intervention: Standard commercial preparation of 0.5% bupivacaine
Number of subjects: 100
Study 3048753 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:400,000 epinephrine
Number of subjects: 100
Study 3048753 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine with 1:400,000 epinephrine (control group)
Number of subjects: 100
Study 31189618 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl (TE)
Number of subjects: 369
Study 30580350 — intervention group
Group type: EXPERIMENTAL
Intervention: No restriction of position (Group A)
Number of subjects: 112
Study 30580350 — intervention group
Group type: COMPARATOR
Intervention: 24 hours bed rest after spinal anesthesia (Group B)
Number of subjects: 112
Study 26006197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/kg PEG powder (17 g in 240 mL water or another beverage) and 5 mg bisacodyl suppository (BD) the day before colonoscopy
Number of subjects: 100
Study 26006197 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g/kg PEG with fruit juices for two days and 5 mg bisacodyl suppository (BD) for two days before colonoscopy
Number of subjects: 100
Study 26006197 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day PEG plus bisacodyl regimen
Number of subjects: 100
Study 26006197 — intervention group
Group type: COMPARATOR
Intervention: Two-day PEG plus bisacodyl regimen
Number of subjects: 100
Study 22659022 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left SMA
Number of subjects: 36
Study 22659022 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left M1
Number of subjects: 36
Study 22659022 — intervention group
Group type: COMPARATOR
Intervention: tDCS(sham)
Number of subjects: 36
Study 21735348 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental physicians trained in upfront agenda setting through the Establishing Focus Protocol, including two hours of training and two hours of coaching per week for four consecutive weeks.
Number of subjects: 1460
Study 21735348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 1460
Study 19731300 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cluster LEDT (69 LEDs with wavelengths 660/850 nm, 10/30 mW, 30 seconds total irradiation time, 41.7 J of total energy irradiated)
Number of subjects: 10
Study 19731300 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cluster LEDT
Number of subjects: 10
Study 17046506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ending Violence curriculum (three-class-session prevention program focused on legal issues)
Number of subjects: 0
Study 14709121 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body skin examinations by GPs
Number of subjects: 3100
Study 14709121 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with increased likelihood of skin examination
Number of subjects: 3100
Study 11782286 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality paper
Number of subjects: 389
Study 11782286 — intervention group
Group type: COMPARATOR
Intervention: Standard quality paper
Number of subjects: 389
Study 9426791 — intervention group
Group type: EXPERIMENTAL
Intervention: QSC + EBF + SBF
Number of subjects: 426
Study 9426791 — intervention group
Group type: COMPARATOR
Intervention: QSC
Number of subjects: 426
Study 9426791 — intervention group
Group type: EXPERIMENTAL
Intervention: QSC + EBF
Number of subjects: 426
Study 9426791 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic susceptibility feedback
Number of subjects: 426
Study 8324855 — intervention group
Group type: COMPARATOR
Intervention: Height-based dosing method
Number of subjects: 7152
Study 8324855 — intervention group
Group type: COMPARATOR
Intervention: Physical appearance dosing method
Number of subjects: 7152
Study 3719535 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day fecal occult blood (FOB) testing
Number of subjects: 26975
Study 3719535 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26975
Study 3719535 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiac (Hemoccult) and immunologic (Feca EIA) FOB tests
Number of subjects: 26975
Study 3719535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing
Number of subjects: 26975
Study 29735039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-reduced nectars with health claim
Number of subjects: 206
Study 29735039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-reduced nectars with hedonic claim
Number of subjects: 206
Study 29735039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-reduced nectars with no claims
Number of subjects: 206
Study 29735039 — intervention group
Group type: COMPARATOR
Intervention: Control product without sugar reduction
Number of subjects: 206
Study 25852131 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation plus low molecular weight heparin and below-knee compression stockings (Group 1)
Number of subjects: 30
Study 25852131 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin and below-knee compression stockings alone (Group 2, control group)
Number of subjects: 30
Study 24662896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (child care centers with healthy menu changes and family-based education)
Number of subjects: 307
Study 24662896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 307
Study 24662896 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control program)
Number of subjects: 307
Study 22202544 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 88
Study 22202544 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise-cancelling headphones group
Number of subjects: 88
Study 22202544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 22202544 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study 20497292 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 42
Study 20497292 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 18031471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg daily)
Number of subjects: 40
Study 18031471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (50 mg daily)
Number of subjects: 40
Study 18031471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18031471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine and Nortriptyline
Number of subjects: 40
Study 16098680 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 52
Study 16098680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11915576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MPA
Number of subjects: 36
Study 11915576 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg MPA
Number of subjects: 36
Study 10736332 — intervention group
Group type: EXPERIMENTAL
Intervention: Background diets (basic foods diet, self‐selected diet at specified times, self‐selected diet eaten ad libitum)
Number of subjects: 8
Study 10736332 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy foods (tofu, tempeh, cooked soybeans, texturized vegetable protein)
Number of subjects: 8
Study 10736332 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone doses of 0.8‐1.4 mg/kg
Number of subjects: 8
Study 10736332 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone bioavailability
Number of subjects: 8
Study 9344322 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for nonextremity sarcomas
Number of subjects: 0
Study 9344322 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 1398472 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment for 6 months
Number of subjects: 21
Study 1398472 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 21
Study 3998766 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic thymosin-alpha 1 (loading dose regimen)
Number of subjects: 42
Study 3998766 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic thymosin-alpha 1 (twice‐weekly schedule)
Number of subjects: 42
Study 3998766 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic thymosin-alpha 1
Number of subjects: 42
Study 3998766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30146344 — intervention group
Group type: EXPERIMENTAL
Intervention: VR942 0.5 mg
Number of subjects: 85
Study 30146344 — intervention group
Group type: EXPERIMENTAL
Intervention: VR942 10 mg
Number of subjects: 85
Study 30146344 — intervention group
Group type: EXPERIMENTAL
Intervention: VR942 20 mg
Number of subjects: 85
Study 30146344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 30146344 — intervention group
Group type: EXPERIMENTAL
Intervention: VR942 (all doses)
Number of subjects: 85
Study 26834046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active encouragement for diagnostic testing and treatment
Number of subjects: 350
Study 26834046 — intervention group
Group type: COMPARATOR
Intervention: Usual care according to the Dutch guideline on urinary incontinence
Number of subjects: 350
Study 24627552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 402
Study 24627552 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 402
Study 23291139 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with S-1
Number of subjects: 240
Study 23291139 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel combined with fluorouracil
Number of subjects: 240
Study 19962730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin spray (40 microg) plus diclofenac sodium suppository (100 mg)
Number of subjects: 150
Study 19962730 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium suppository (100 mg) plus placebo spray (normal saline 0.9%)
Number of subjects: 150
Study 18375325 — intervention group
Group type: COMPARATOR
Intervention: Standard tranexamic acid dosing regimen (10 mg/kg over 20 minutes, followed by 1 mg/kg/h)
Number of subjects: 20
Study 18375325 — intervention group
Group type: EXPERIMENTAL
Intervention: New tranexamic acid dosing schedule
Number of subjects: 20
Study 18375325 — intervention group
Group type: EXPERIMENTAL
Intervention: New dosing protocol for tranexamic acid
Number of subjects: 20
Study 15972907 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR with polyradial femur
Number of subjects: 55
Study 15972907 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR with single radius design
Number of subjects: 55
Study 15972907 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR with cam-post mechanism
Number of subjects: 55
Study 15972907 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR without cam-post mechanism
Number of subjects: 55
Study 15972907 — intervention group
Group type: COMPARATOR
Intervention: Normal knees
Number of subjects: 55
Study 12795227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianbaokang Injection
Number of subjects: 70
Study 12795227 — intervention group
Group type: COMPARATOR
Intervention: Contrast group (not specified intervention)
Number of subjects: 70
Study 10392941 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement indicated based on different hemodynamic criteria
Number of subjects: 136
Study 10392941 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual mean pressure gradient of > 5 and < 10 mm Hg
Number of subjects: 136
Study 8907442 — intervention group
Group type: EXPERIMENTAL
Intervention: StairMaster training
Number of subjects: 12
Study 8907442 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 12
Study 31054935 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate (T-C) solution
Number of subjects: 86
Study 28220514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh FMT product
Number of subjects: 72
Study 28220514 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen FMT product
Number of subjects: 72
Study 28220514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilised FMT product
Number of subjects: 72
Study 28220514 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 72
Study 27003917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg load followed by a continuous infusion of 0.5 μg/kg/h)
Number of subjects: 142
Study 27003917 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 142
Study 25216660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrestorative caries treatment (NRCT; no caries removal, opening up the cavity, teaching brushing and fluoride application)
Number of subjects: 169
Study 25216660 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional restorations (CR; complete caries removal and compomer restoration)
Number of subjects: 169
Study 25216660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall technique (HT; no caries removal, sealing in with stainless steel crowns)
Number of subjects: 169
Study 25216660 — intervention group
Group type: COMPARATOR
Intervention: NRCT
Number of subjects: 169
Study 25216660 — intervention group
Group type: COMPARATOR
Intervention: CR
Number of subjects: 169
Study 25216660 — intervention group
Group type: COMPARATOR
Intervention: HT
Number of subjects: 169
Study 21908204 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) supplementation (600 mg daily for 8 weeks)
Number of subjects: 63
Study 21908204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 18810386 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive Watson‐Jones approach (MIS group)
Number of subjects: 40
Study 18810386 — intervention group
Group type: COMPARATOR
Intervention: Transgluteal Bauer approach (control group)
Number of subjects: 40
Study 15729082 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (3.6±1.5 mg/day)
Number of subjects: 40
Study 12793117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 350
Study 12793117 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological therapy alone)
Number of subjects: 350
Study 11253475 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activation markers (CD62) measured on the 1st (2.6 +/‐ 1.4%), 3rd (3.5 +/‐ 2.3%), and 7th (3.0 +/‐ 2.0%) day after stroke onset
Number of subjects: 50
Study 11253475 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activation markers (CD63) measured on the 1st (1.9 +/‐ 0.6%) and 3rd (2.0 +/‐ 0.6%) day after stroke onset
Number of subjects: 50